AstraZeneca and Merck Report Results of Lynparza (olaparib) in P-III SOLO3 Study for Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer #ASCO2019
Shots:
- The P-III SOLO3 study results involves assessing of Lynparza (300mg- bid) vs CT (paclitaxel/topotecan /pegylated liposomal doxorubicin/gemcitabine) in 266 patients in a ratio (2:1) with 2L+ platinum-sensitive relapsed BRCA1/2-mutated (gBRCAm) advanced ovarian cancer
- The P-III SOLO3 study results: improvement in ORR (72.2% vs 51.4%); PFS (13.4 mos. vs 9.2mos.); safe & tolerable- presented at ASCO 2019
- Lynparza is a PARP inhibitor- targeted for DNA damage response (DDR) pathway deficiencies- including BRCA mutations and has received approval in 64 & 38 countries as a maintenance treatment of platinum-sensitive relapsed ovarian cancer & 1L gBRCAm HER2- metastatic breast cancer respectively
Click here to read the full press release
Ref: AstraZeneca | Image: AstraZeneca
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com